Clinical Trial Update: Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating Pegasys (pegylated interferon alfa-2a) plus ribavirin in patients with hepatitis C and thalassemia; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Thalassemia

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Baqiyatallah Medical Sciences University | Conditions: Hepatitis C, Thalassemia | Phase 4 | Status: COMPLETED